Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, Date of authorisation: 23/04/2007, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 3 July 2026 - 8:52

Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, Date of authorisation: 23/04/2007, Revision: 29, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 3 July 2026 - 8:44

Clinical Trials Information System (CTIS): Information day, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 June 2026, 12:30 (CEST) to 17 June 2026, 17:30 (CEST)

Medicine shortage communication (MSC): TEGSEDI® (inotersen sodium, 284 mg solution for injection in prefilled syringe): planned marketing cessation (discontinuation)

Submitted by Anonymous (not verified) on 3 July 2026 - 8:16

Medicine shortage communication (MSC): TEGSEDI® (inotersen sodium, 284 mg solution for injection in prefilled syringe): planned marketing cessation (discontinuation)

Opinion/decision on a Paediatric investigation plan (PIP): Rezzayo, rezafungin acetate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0343/2024

Submitted by Anonymous (not verified) on 3 July 2026 - 8:00

Opinion/decision on a Paediatric investigation plan (PIP): Rezzayo, rezafungin acetate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0343/2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More